Hematology & Oncology
Division of Hematology and Oncology
 |
Nam H. Dang, MD, PhD Division of Hematology/Oncology Professor and Deputy Division Chief University of Florida Shands Cancer Center Director, UFSCC Clinical Trials Office 1600 SW Archer Road- Box 100278 Gainesville, FL 32610 |
Nam H. Dang, MD, PhD is a board certified medical oncologist with expertise in the study and treatment of lymphoma and chronic lymphocytic leukemia (CLL). He is Professor and Deputy Chief of the Division of Hematology & Oncology as well as Director of the University of Florida Shands Cancer Center Clinical Trials Office.
Training:
| Degree Program |
Institution | Field/Specialty |
| A.B. (Magna Cum Laude) | Harvard University | Biochemical Sciences |
| PhD | Harvard University | Immunology |
| MD (Magna Cum Laude) | Harvard Medical School | Medicine |
| Residency | Massachusetts General Hospital | Internal Medicine |
| Fellowship | Dana-Farber Cancer Institute | Medical Oncology |
Clinical Interests:
Diagnosis and Treatment of Lymphoma and Chronic Lymphocytic Leukemia (CLL)
Research Interests:
Dr Dang’s primary research effort emphasizes the development of novel treatment strategies for patients with lymphoma/CLL through the identification of new targets and the utilization of novel targeted therapies. To achieve this aim, he has conducted multiple clinical trials and is active in laboratory research with the goal of translating laboratory findings to the clinical setting for the ultimate benefit of the patient.
Representative Publications:
- Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, and Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin’s lymphoma. Journal of Clinical Oncology 22:4095-4102, 2004.
- Yamochi T, Yamochi T, Aytac U, Sato T, Sato K, Ohnuma K, McKee KS, Morimoto C, and Dang NH. Regulation of p38 phosphorylation and topoisomerase II alpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. Cancer Research 65:1973-1983, 2005.
- Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K, McKee KS, Morimoto C, and Dang NH. CD26 regulates p38 MAPK-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Research 65:6950-6956, 2005.
- Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, and Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin’s lymphoma. British Journal of Haematology 136:439-447, 2007.
- Dang NH, Fayad L, McLaughlin P, Romaguera JE, Hagemeister F, Goy A, Neelapu S,Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, and Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non- Hodgkin’s lymphoma. British Journal of Haematology 138:502-505, 2007
- Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, and Dang NH. CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. British Journal of Cancer. In Press.2009